Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-23-022462
Filing Date
2023-05-16
Accepted
2023-05-16 16:06:54
Documents
15
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A achv-20221231.htm   iXBRL 10-K/A 1024282
2 EX-23.1 achv-ex23_1.htm EX-23.1 4198
3 EX-31.1 achv-ex31_1.htm EX-31.1 6743
  Complete submission text file 0000950170-23-022462.txt   1292086

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT achv-20221231_pre.xml EX-101.PRE 20643
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT achv-20221231_def.xml EX-101.DEF 20093
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT achv-20221231.xsd EX-101.SCH 2929
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT achv-20221231_lab.xml EX-101.LAB 25199
9 EXTRACTED XBRL INSTANCE DOCUMENT achv-20221231_htm.xml XML 11974
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 033-80623 | Film No.: 23927503
SIC: 2835 In Vitro & In Vivo Diagnostic Substances